Marks J W, Baum R A, Hanson R F, Hersh T, Hightower N C, Mekhjian H, Schaefer R A, Soloway R D, Thistle J L, Thomas F B
Ann Intern Med. 1984 Mar;100(3):382-4. doi: 10.7326/0003-4819-100-3-382.
During the National Cooperative Gallstone Study, therapy with chenodiol, 750 or 375 mg/d, for 2 years resulted in confirmed, complete gallstone dissolution in 14% and 5% of patients, respectively, and partial dissolution (greater than 50%) in 27% and 18%. The present study was done to determine the frequency with which complete dissolution occurs in patients having partial dissolution of gallstones who receive additional therapy. Eighty-six of one hundred thirty-eight eligible patients continued to receive 750 mg/d (61 patients) or 375 mg/d (25 patients) of chenodiol for 1 year. Patients whose oral cholecystogram at the end of the year showed further (greater than 50%) dissolution continued to receive chenodiol, (28 patients at 750 mg/d and 11 patients at 375 mg/d) for a second year (total duration of therapy, 4 years). A final oral cholecystogram was taken at the end of the fourth year. Complete dissolution occurred in 23% and 16% of patients receiving chenodiol, 750 or 375 mg/d, respectively, for an additional 1 or 2 years.
在全国胆石症合作研究中,服用鹅去氧胆酸,剂量为750毫克/天或375毫克/天,治疗2年,结果分别有14%和5%的患者结石得到确诊且完全溶解,27%和18%的患者结石部分溶解(超过50%)。本研究旨在确定在接受额外治疗的胆石部分溶解患者中完全溶解发生的频率。138名符合条件的患者中有86名继续服用750毫克/天(61名患者)或375毫克/天(25名患者)的鹅去氧胆酸,为期1年。年末口服胆囊造影显示结石进一步(超过50%)溶解的患者继续服用鹅去氧胆酸(750毫克/天的28名患者和375毫克/天的11名患者),为期第二年(总治疗时长4年)。在第四年末拍摄最后一张口服胆囊造影照片。在额外服用鹅去氧胆酸1年或2年的患者中,服用750毫克/天或375毫克/天的患者分别有23%和16%出现完全溶解。